CD274 and neoplasm: Although the prevalence of patients with PD-L1-negative tumors was low (21%), these results suggest an association between PD-L1-positive expression on tumor and immune cells measured by the investigational 22C3 assay and increased antitumor activity, which has also been observed in the second- and third-line G/GEJ cohort in JVDF [26], and in the pretreated G/GEJ cohort of KEYNOTE-059 [16].